The filing is routine and does not affect the stock's fundamental outlook. However, the combination of a late 10-Q, auditor change, and delayed proxy filing suggests potential control weaknesses. Monitor for the eventual definitive proxy statement and any subsequent restatements or SEC inquiries.
Price Chart
Executive Summary
Q/C Technologies filed Amendment No. 1 to its 2025 10-K solely to add Part III items (director/executive compensation, beneficial ownership, related transactions, and auditor fees) that were omitted from the original filing. The amendment does not change any financial statements or previously reported results. The filing follows a recent auditor change (March 2026) and a late 10-Q filing notice (November 2025), but this amendment is purely administrative.
Key Facts
- Amendment adds only Part III items (10, 11, 12, 13, 14) omitted from original 10-K filed March 15, 2026.
- No changes to financial statements, business operations, or risk factors.
- Auditor changed from Stephano Slack to Grassi & Co. on March 9, 2026, disclosed in prior 8-K.
- Late NT 10-Q filed November 14, 2025 for Q3 2025; no restatement noted in this amendment.
- PharmaCyte Biotech Inc. owns 44.90% of common stock as of April 26, 2026.
- Executive Chairman Joshua Silverman entered a new 3-year employment agreement on April 13, 2026.
Financial Impact
No financial impact from this administrative amendment.
Risk Factors
- Potential ongoing internal control or financial reporting issues given the late filing and auditor change.
- Concentrated ownership by PharmaCyte (44.9%) could lead to governance or control events.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001493152-26-019663 |
| Exhibit: ex32-1.htm | 0001493152-26-019663 |
| Exhibit: ex32-2.htm | 0001493152-26-019663 |
| Document: 0001493152-26-019663-index-headers.html | 0001493152-26-019663 |
| Document: 0001493152-26-019663-index.html | 0001493152-26-019663 |
| Document: 0001493152-26-019663.txt | 0001493152-26-019663 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $0.7753 | awaiting T+20 | — | $0.4500 (−41.96%) |
Sep 30, 2026 26d ago | Press Release | $0.8511 | awaiting T+20 | — | $0.4500 (−47.13%) |
Sep 18, 2026 5w ago | 8-K | $0.7847 $0.5000 | ▼ −36.28% | ▼ −35.37% | $0.4500 (−42.65%) |
Jul 2, 2026 16w ago | 8-K | $3.85 $2.71 | ▼ −29.61% | ▼ −29.20% | $0.4500 (−88.31%) |
Apr 29, 2026 25w ago | 10-K/A | $3.75 $4.37 | ▲ +16.53% | ▲ +11.31% | $0.4500 (−88.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers